NINLARO is made by Takeda Pharmaceutical Company Limited.
The Manufacturer of NINLARO
Takeda Pharmaceutical Company Limited is the global pharmaceutical company responsible for NINLARO® (ixazomib) capsules. This medication, known by its generic name ixazomib and development code MLN9708, is recognized as the first oral proteasome inhibitor.
Takeda announced the approval of NINLARO® capsules by the Japanese Ministry of Health, Labour and Welfare on March 30, 2017, from Osaka, Japan. This significant milestone underscored Takeda's commitment to developing innovative treatments.
Key Details About NINLARO's Origin
To provide a clear overview, here are some essential details regarding NINLARO and its developer:
| Aspect | Detail |
|---|---|
| Manufacturer | Takeda Pharmaceutical Company Limited |
| Drug Name | NINLARO® capsules |
| Generic Name | Ixazomib |
| Development Code | MLN9708 |
| Drug Type | Oral Proteasome Inhibitor |
| Significant Event | Approval by the Japanese Ministry of Health, Labour and Welfare |
| Announcement Date | March 30, 2017 |
| Announcement Origin | Osaka, Japan |
As a leading global biopharmaceutical company, Takeda Pharmaceutical Company Limited focuses on R&D-driven innovation to deliver life-changing treatments. Their portfolio includes therapies for oncology, rare diseases, neuroscience, and gastroenterology, among others.
